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These	 correlations	 were	 not	 apparent	 when	 perfusate	 levels	 were	 considered.	
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1 |  INTRODUCTION
Hypothermic	oxygenated	machine	perfusion	(HOPE)	is	
gaining	increasing	interest	as	a	tool	to	reduce	ischemia-	
reperfusion	 injury	 and	 to	 improve	 outcomes	 of	 liver	
transplantation	 (LT).	 In	 clinical	 studies,	 HOPE	 use	




be	 manifold,	 being	 related	 to	 adenosine-	triphosphate	
replenishment,	 immunomodulation,7	 better	 preserva-
tion	of	endothelial	cells	glycocalyx,	peri-	biliary	vascular	
plexus,	and	peribiliary	glands,8,9	and,	more	importantly,	




of	 reactive	 oxygen	 species	 by	 reverse	 electron	 transfer	
upon	 organ	 reperfusion,11,12	 thus	 resulting	 in	 dimin-






Microdialysis	 (MD)	 is	 a	 technique	 by	 which	 inter-
stitial	 fluid	 (microdialysate)	 can	 be	 sampled	 from	 a	
variety	of	tissues	to	measure	the	concentration	of	me-
tabolites	such	as	glucose,	lactate,	pyruvate,	and	gluta-




to	 assess	 liver	 metabolism	 during	 the	 phases	 of	 liver	
retrieval,	 cold	 preservation	 and	 after	 graft	 implanta-
tion,18–	22	and	explored	as	a	 tool	 for	early	detection	of	
ischemic	complications	and	acute	rejection.23–	29	As	ap-
plied	 to	 machine	 perfusion,	 MD	 has	 the	 potential	 of	
allowing	 monitoring	 of	 liver	 metabolism	 throughout	




as	a	potential	 tool	 to	discriminate	 lung	 function	after	
transplantation.30	 MD	 has	 been	 occasionally	 used	 in	
the	setting	of	kidney	machine	perfusion31–	33	but,	to	the	






2 |  PATIENTS AND METHODS
2.1 | Study design
This	 was	 a	 prospective,	 open-	label	 observational	 pilot	
study	 on	 10	 consecutive	 grafts	 treated	 with	 dual-	HOPE	
(i.e.,	double	cannulation	of	both	portal	vein	and	hepatic	
artery—	D-	HOPE)	 in	 the	 period	 October	 2019–	January	
2020	 at	 our	 Institution.	 The	 study	 was	 approved	 by	 the	
local	 ethics	 committee	 (resolution	 nr.	 739	 of	 June	 10,	
2019).	 Patients	 signed	 a	 consent	 form	 for	 receiving	 an	
organ	treated	with	machine	perfusion	and	for	participat-
ing	in	the	study.	All	study	procedures	complied	with	the	
Declaration	 of	 Helsinki	 and	 the	 Declaration	 of	 Istanbul	
(https://www.wma.net).	 Recipients	 of	 DBD	 grafts	 in-
cluded	in	this	study	were	also	included	in	a	recently	pub-
lished	 study	 on	 the	 value	 of	 perfusate	 analysis	 during	
D-	HOPE	in	predicting	outcome	after	LT.34
Our	 machine	 perfusion	 and	 LT	 protocols	 have	 been	
previously	 described.4,34–	36	 At	 our	 Institution,	 the	 use	






was	 applied	 for	 a	 minimum	 of	 90  min	 during	 recipient	
hepatectomy.	The	liver	graft	was	weighed	before	and	after	
machine	 perfusion	 to	 detect	 swelling	 during	 machine	
perfusion.
MD	 was	 used	 to	 sample	 extracellular	 fluid	 during	
back	 table	 preparation	 and	 subsequent	 machine	 perfu-
sion.	 Study	 design	 and	 timing	 of	 sample	 collection	 are	
summarized	 in	 Figure  1.	 Briefly,	 the	 liver	 was	 perfused	
with	Celsior®	(IGL,	Lisseu,	France)	at	retrieval	and	trans-
ported	in	SCS	at	our	center.	The	liver	was	unpacked	upon	
arrival	 and,	 before	 the	 start	 of	 back	 table	 preparation,	











of	 microdialysate	 appeared	 at	 the	 tip	 of	 the	 connection	
needle	and	discarded	after	30 min	 to	allow	fluid	equili-
bration,	as	 recommended.13,38,39	The	 second	vial,	 which	
was	the	first	 to	be	analyzed,	was	collected	at	the	end	of	
backtable	preparation,	at	least	one	hour	after	having	been	
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positioned,	and	was	therefore	representative	of	liver	me-
tabolism	 during	 the	 last	 part	 of	 SCS.	 Subsequently,	 the	
liver	was	connected	to	the	perfusion	device	with	the	MD	
catheter	 in	 place	 and	 MD	 vials	 were	 changed	 hourly	
during	D-	HOPE.	Thus,	at	least	3	MD	samples	were	avail-
able	for	every	single	procedure:	the	first	representing	the	
terminal	 phase	 of	 SCS,	 and	 the	 remaining	 two	 samples	
the	D-	HOPE	phase.	When	D-	HOPE	time	was	<120 min,	
the	last	MD	sample	was	collected	at	the	end	of	machine	
























(TNFα),	 toll-	like	 receptor-	4	 (TLR-	4),	 intercellular	 adhesion	





injury	 and	 steatosis	 were	 determined	 on	 liver	 biopsies	 ob-
tained	at	the	end	of	transplant.	Tissue	samples	were	fixed	and	
processed	 to	 obtain	 5-	µm-	thick	 sections.	 Hematoxylin	 and	
eosin,	periodic	acid-	Schiff,	and	periodic	acid-	Schiff-	diastase	
staining	 were	 performed	 to	 evaluate	 steatosis,	 necrosis,	 as	
well	as	glycogen	content	and	distribution.









analyzed	with	 regards	 to	 their	 correlation	with	outcome	
measures,	as	outlined	below.
2.2 | Outcome measures
Primary	outcome	measures	were	early	allograft	dysfunc-
tion	 (EAD)42	 and	 L-	GrAFT	 score.43	 Secondary	 outcome	
measures	were	duration	of	hospital	stay,	onset	and	grade	
of	acute	kidney	injury	(AKI),44	and	comprehensive	com-
plication	 index45	 (CCI)	 calculated	 at	 hospital	 discharge	
and	at	6-	month	follow-	up.	Graft	survival	and	occurrence	
of	 biliary	 complications	 were	 also	 evaluated.	 Minimum	
follow-	up	was	6 months.
2.3 | Statistical analysis
Variables	 were	 expressed	 as	 number	 (%)	 or	 median	
(interquartile	 range)	 and	 compared	 using	 standard	
parametric	 and	 non-	parametric	 tests.	 All	 perfusate	
values	 were	 normalized	 to	 liver	 weight.	 For	 repeated	
F I G U R E  1  Synopsis	of	study	design
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measures	ANOVA,	normal	distribution	of	variables	was	
verified	 by	 Shapiro–	Wilk	 test	 and	 by	 visual	 inspection	
using	 quantile-	quantile	 plots.	 p-	values	 of	 pairwise	 t-	
tests	 between	 different	 timepoints	 were	 adjusted	 using	
the	 Bonferroni	 multiple	 testing	 correction	 method.	
Correlation	 between	 variables	 was	 evaluated	 using	




ber	 of	 D-	HOPE	 procedures	 per	 year	 at	 our	 Institution.	
All	 analyses	 were	 performed	 using	 R	 version	 3.6.3	 (R	
Foundation	 for	Statistical	Computing,	Vienna,	Austria.	
https://www.R-	proje	ct.org/).
3 |  RESULTS
3.1 | D- HOPE procedure and clinical 
outcome
Recipient	and	donor	features	are	summarized	in	Table 1.	






1)	 and	 donation	 after	 circulatory	 death	 (case	 2).	 Table  2	
summarizes	 times	 and	 graft	 weight	 before	 and	 after	 ma-
chine	 perfusion.	 Cold	 ischemia	 and	 D-	HOPE	 time	 were	
344	(295,	367)	and	116	(103,	143)	min.	In	3	grafts	weight	





occasional	 mild	 bleeding	 from	 MD	 catheter	 entry	 site	
was	 easily	 controlled	 by	 diathermy.	 No	 patient	 devel-
oped	catheter-	related	bleeding	or	intra-	or	extra-	hepatic	
hematoma,	 as	 assessed	 by	 ultrasound	 scan	 performed	
after	LT.
Study	 variables	 and	 outcome	 measures	 are	 summa-
rized	in	Table 3.	Three	patients	developed	EAD	after	LT	
and	 one	 later	 developed	 delayed	 non-	function	 and	 re-
quired	 retransplantation.	All	 three	patients	had	a	 trans-
aminase	 peak	 ≥2000  IU,	 whereas	 only	 the	 patient	 who	







T A B L E  1  Baseline	characteristics	of	recipients	and	donors
Recipient features Donor features







1 M 68 27 ETOH+NASH No 15 75 DBD 45 20 70
2 M 60 27 PBC Yes 11 60 DCD.3 26 1 5
3a M 62 33 ETOH+NASH yEs 8 48 DBD 37 25 30
4b M 53 33 HCV+NASH Yes 20 63 DBD 29 40 30
5 M 66 22 ETOH No 13 58 DBD 41 5 35
6a F 64 21 ETOH No 13 83 DBD 23 10 60
7 F 63 26 HBV+NASH Yes 9 83 DBD 24 3 40
8 F 61 18 HBV+HDV Yes 18 80 DBD 27 10 70
9 M 67 27 NASH Yes 9 53 DBD 34 1 2
10 F 66 28 NASH Yes 9 83 DBD 20 0 5
Median 63 23 12 69 28 7 32
25th	% 61 27 9 59 24 1 11
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Concerning	baseline	variables,	the	only	significant	dif-
ference	 between	 EAD	 and	 non-	EAD	 cases	 was	 a	 higher	
percentage	 of	 macrovesicular	 steatosis	 (25%	 vs.	 3%,	
p  =  0.04)	 in	 EAD	 group.	 Degree	 of	 macrovesicular	 ste-
atosis	was	25%	and	10%	 in	patients	who	recovered	 from	





at	 6-	month	 follow-	up,	 as	 demonstrated	 by	 a	 higher	 CCI	
(47.4	vs.	22.6,	p = 0.05).	Only	patient	4	developed	Clavien-	
Dindo	≥3b	 complications,	 represented	 by	 coagulopathy-	
















3.2 | Microdialysate and perfusate 
metabolites


















Kinetics	 of	 MD	 lactate	 and	 glucose	 was	 different	 in	
grafts	 that	 developed	 EAD	 (Figure  2).	 In	 particular,	 lev-
els	of	glucose	and	lactate	were	significantly	higher	during	
2nd	 hour	 of	 D-	HOPE	 (244	 vs.	 121  mg/dl,	 p  =  0.03	 and	
4.9	vs.	2.7 mmol/L,	p = 0.03)	(Table S2).	In	contrast	with	
glucose	and	lactate	levels	on	perfusate,	levels	of	MD	me-
tabolites	 clearly	 diverged,	 being	 significantly	 higher	 in	
dysfunctioning	grafts	at	two	hours	of	machine	perfusion	




















1 47 341 95 106 1550 1480 −4 30 491
2 37 360 94 147 1370 1370 0 23 550
3 57 369 130 103 2290 2410 +5 25 508
4 80 443 120 131 2400 2800 +17 37 614
5 67 407 135 103 1980 2090 +6 21 530
6 48 291 72 151 1500 1480 −1 24 497
7 41 296 115 125 1180 1120 −5 21 453
8 35 295 105 190 1000 1010 +1 24 524
9 43 348 170 91 1750 1760 +1 21 474
10 50 268 110 101 940 960 +2 22 404
Median 47 344 112 116 1525 1480 0.8 23 502
25th	% 41 295 97 103 1227 1182 −1.0 21 478
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T A B L E  3  Study	variables	in	the	whole	series	and	according	to	the	onset	of	early	allograft	dysfunction
Overall EAD No EAD
p10 3 7
Recipient	age	(years) 63.5	[61.0,	66.3] 62.1	[57.7,	63.0] 65.8	[61.8,	66.6] 0.21
Recipient	BMI 26.8	[23.1,	28.1] 33.1	[27.1,	33.1] 26.7	[24.1,	27.1] 0.30
Donor	age	(years) 69.1	[58.6,	82.2] 63.5	[55.9,	73.4] 74.8	[59.1,	81.5] 0.73
Donor	BMI 28.0	[24.4,	36.1] 29.3	[26.2,	33.0] 26.8	[25.0,	37.6] 0.91
Donor	ICU	stay	(days) 4.0	[3.2,	5.5] 4.0	[3.0,	5.0] 4.0	[3.5,	5.5] 0.72
Donor	GGT	(IU/L) 25	[18,	46] 32.00	[25,	41] 23	[15,	93] 0.65
Macrosteatosis	(%) 7.5	[1.5,	17.5] 25.0	[17.5,	32.5] 3.0	[1.0,	7.5] 0.04
Microsteatosis	(%) 32.5	[11.2,	55.0] 30.0	[30.0,	45.0] 35.0	[5.0,	55.0] 0.91
Donor	hepatectomy	(min) 47	[41,	55] 57	[52,	68] 43	[39,	48] 0.09
Cold	ischemia	time	(min) 344	[29,	366] 369	[330,	406] 341	[295,	354] 0.42
Backtable	time	(min) 112	[97,	127] 120	[96,	125] 110	[100,	125] 0.91
D-	HOPE	(min) 113	[103,	123] 120	[111,	120] 106	[98,	136] 1.00
Graft	weight	pre	(g) 1525	[1227,	1922] 2,290	[1895,	2345] 1,370	[1090,	1650] 0.09
Graft	weight	post	(g) 1,480	[1182,	2007] 2,410	[1945,	2605] 1,370	[1065,	1620] 0.07
Delta	weight	(%) 0.80	[−0.98,	4.43] 5.20	[1.95,	10.95] 0.60	[−2.25,	1.55] 0.30
Total	preservation	(min) 502	[478,	528] 508	[502,	561] 491	[463,	527] 0.30
Surgery	time	(min) 365	[287,	455] 395	[354,	455] 335	[278,	448] 0.42
PRBC	units 4.0	[4.0,	7.5] 4.0	[4.0,	4.0] 6.0	[2.0,	10.5] 0.48
End	lactate	(mmol/L) 2.15	[1.48,	2.30] 2.10	[1.60,	2.15] 2.30	[1.65,	2.30] 0.42
Induction	(basiliximab) 8	(80.0%) 3	(100.0%) 5	(71.4%) 0.86
Day	of	IS	start 0.24
0 3	(30.0%) 1	(33.3%) 2	(28.6%)
1 6	(60.0%) 1	(33.3%) 5	(71.4%)
4 1	(10.0%) 1	(33.3%) 0	(0.0%)
AST	peak	(IU/L) 1,020	[676,	1850] 3,375	[2695,	7725] 721	[616,	1020] 0.02
ALT	peak	(IU/L) 837	[463,	1003] 1,000	[937,	1048] 510	[419,	902] 0.21
Bilirubin	day	7th	(mg/dl) 2.0	[1.4,	4.8] 5.5	[3.1,	9.0] 2.0	[1.5,	2.4] 0.57
INR	day	7th 1.2	[1.2,	1.3] 1.3	[1.3,	1.4] 1.2	[1.2,	1.3] 0.64
ALP	day	7th	(IU/L) 192.0	[143.8,	231.5] 237.0	[169.0,	340.5] 170.0	[149.5,	214.5] 0.49
L-	GrAFT	(risk	%) 8.7	[7.7,	19.2] 22.1	[15.6,	51.3] 7.9	[6.3,	9.4] 0.09
AKI	stage 0.28
No	AKI 2	(20.0%) 1	(33.3%) 1	(14.3%)
1 5	(50.0%) 1	(33.3%) 4	(57.1%)
2 2	(20.0%) 0	(0.0%) 2	(28.6%)
3 1	(10.0%) 1	(33.3%) 0	(0.0%)
Clavien-	Dindo	≥3	complications 2	(20.0%) 2	(66.7%) 0	(0.0%) 0.12
Hospital	CCI 21.7	[11.7,	27.8] 33.5	[16.7,	51.5] 20.9	[14.8,	22.6] 0.42




















viving	 grafts	 that	 initially	 developed	 EAD	 subsequently	
developed	 biliary	 complications,	 including	 one	 case	 of	
ischemic	cholangiopathy.
3.3 | Microdialysate and perfusate FMN
Figure  5	 depicts	 FMN	 levels	 in	 perfusate	 and	 microdi-
alysate.	 As	 opposed	 to	 glucose	 and	 lactate,	 FMN	 levels	
in	 microdialysate	 significantly	 dropped	 after	 initiation	
of	 D-	HOPE,	 independently	 of	 graft	 function.	 In	 con-
trast,	 adjusted	 and	 non-	adjusted	 perfusate	 FMN	 levels	
were	 higher	 in	 grafts	 who	 developed	 early	 dysfunction,	
although	this	difference	did	not	achieve	statistical	signifi-
cance	 (Table S4).	The	only	graft	 that	developed	delayed	






3.4 | Histology and expression of 
inflammatory cytokines
Histological	 injury	 (Figure  7—	Panel	 A)	 correlated	 with	
EAD	onset	and	was	more	severe	in	the	graft	that	required	
retransplantation.	 Interestingly,	 reduced	 glycogen	 con-
tent	was	observed	in	grafts	that	subsequently	developed	
EAD.	Upon	reperfusion,	a	significant	increase	of	inflam-
matory	 cytokines	 (IL-	6,	 IL-	8,	 and	 TNFα)	 and	 adhesion	
molecules	 (ICAM1)	 expression	 was	 observed,	 with	 no	




tissue	 content	 exhibited	 a	 downward	 trend	 from	 cold	
preservation	to	reperfusion	into	recipient,	with	no	signifi-
cant	differences	between	study	groups	(Figure S1).
4 |  DISCUSSION
In	the	setting	of	clinical	LT,	the	use	of	MD	has	been	ex-
plored	 mainly	 as	 a	 tool	 for	 monitoring	 and	 early	 detec-















of	 approximately	 300  μmol/L,	 which	 progressively	 nor-
malize	in	the	hours	following	graft	reperfusion.20	In	con-
trast,	pyruvate	quickly	becomes	undetectable	during	SCS	




The	 release	 of	 glucose	 in	 the	 extracellular	 space	 rep-
resents	a	hepatic-	specific	response	to	ischemia	and	it	has	
been	interpreted	as	a	result	of	glycogen	breakdown.19	In	
other	 tissues,	 ischemic	 events	 are	 associated	 with	 very	
low	 interstitial	glucose.	 Interestingly,	 the	 rate	of	glucose	
and	lactate	accumulation	increases	during	implantation19	
and	back	 table	preparation,21	 suggesting	a	potential	 role	
for	 temperature	 during	 these	 phases.	 Previous	 studies	
have	suggested	a	prognostic	value	of	MD	metabolites,	as	
patients	developing	initial	poor	function	had	higher	MD	





in	 the	 extracellular	 space	 upon	 initiation	 of	 D-	HOPE	
and	their	levels	correlate	with	other	known	predictors	of	
graft	 function	 (cold	 ischemia	 time	 and	 macrosteatosis),	
FMN	perfusate	level,	graft	dysfunction,	and	worse	clinical	
outcome.
In	 our	 study,	 D-	HOPE	 did	 not	 alter	 pyruvate	 and	
glutamate	 levels,	 as	 compared	 to	 the	 expected	 kinetics	
during	 SCS.	 In	 particular,	 pyruvate	 levels	 were	 almost	
undetectable	 and	 glutamate	 levels	 were	 constantly	 high,	
in	 keeping	 with	 findings	 from	 previous	 studies.20	 The	
lower	 end-	ischemic	 lactate	 (~1900  μmol/L)	 and	 gluta-
mate	(~200 μmol/L)	concentrations	observed	in	our	study	





constantly	 very	 low	 levels	 of	 MD	 glutamate	 during	 back	
table	and	D-	HOPE.
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turn	resulted	in	increased	glucose	release.	The	composi-
tion	of	the	perfusion	fluid	used	for	D-	HOPE,	containing	















F I G U R E  3  Line	plots	depicting	trend	of	glucose	and	lactate	in	perfusate	(green	and	light	green)	and	microdialysate	(blue	and	light	
blue),	according	to	subsequent	development	of	early	allograft	dysfunction.	In	cases	in	which	D-	HOPE	time	was	<120 min,	2nd	hour	samples	
were	collected	at	the	end	of	machine	perfusion.	Values	are	represented	as	mean ± standard	error	(vertical	error	bars)
F I G U R E  4  Correlation	of	2nd	hour	MD	metabolites	with	L-	GrAFT	score,	6-	month	CCI,	and	graft	characteristics
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the	renal	cortex	has	also	been	observed	in	a	study	using	
MD	 in	 a	 model	 of	 hypothermic	 perfusion	 of	 porcine	
kidneys.33
Whatever	 the	 mechanism,	 glucose	 and	 lactate	 re-
leased	 in	 the	extracellular	 space	during	D-	HOPE	can	be	
interpreted	 as	 markers	 of	 graft	 injury.	 The	 rise	 of	 MD	
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partment,	 did	 not	 seem	 to	 entirely	 capture	 metabolic	
changes	 happening	 at	 a	 cellular	 level,	 a	 finding	 that	 was	
more	evident	for	glucose	and	which	is	in	keeping	with	our	























developed	 EAD	 and	 with	 the	 highest	 levels	 observed	 in	
the	only	failing	graft	of	this	series	(Figure 5).	This	finding,	
which	is	in	keeping	with	those	from	Mueller	et	al.,40	also	






release	 of	 glucose	 and	 lactate	 in	 the	 extracellular	 space	
during	 D-	HOPE,	 highlighting	 their	 potential	 as	 viability	
markers.	Noteworthy,	these	metabolites	can	be	measured	
point-	of-	care	using	MD	equipment	during	D-	HOPE.
This	 study	 has	 numerous	 implications.	 First,	 it	 con-
firms	that	precious	information	on	graft	function	and	in-
jury	can	be	gathered	also	during	hypothermic	perfusion,	
challenging	 the	 concept	 that	 normothermic	 perfusion	 is	
a	 prerequisite	 for	 graft	 viability	 assessment.47,48	 Second,	
while	perfusate	analysis	appears	handier,	 this	 study	and	
previous	 experiences23,24,27,28	 suggest	 that	 MD	 is	 feasible	
without	 major	 modifications	 of	 routine	 practice.	 In	 our	
opinion,	 microdialysate	 and	 perfusate	 analysis	 should	
be	 seen	 as	 complementary	 rather	 than	 alternative	 tech-
niques,	as	metabolites	kinetics	appears	to	be	different	in	
these	 two	 compartments.	 Real-	time	 assessment	 of	 graft	




F I G U R E  6  Correlation	of	2nd	hour	perfusate	FMN	with	L-	GrAFT	score,	6-	month	CCI,	and	2nd	hour	MD	metabolites
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Third,	 this	pilot	 study	 represents	a	baseline	based	on	
which	other	potential	applications	of	MD	during	machine	
perfusion	could	be	explored.	 In	a	recent	study	on	perfu-
sate	 analysis	 during	 D-	HOPE,34	 we	 identified	 alanine	





matory	 cytokines,	 as	 also	 suggested	 by	 a	 recent	 study.49	
Finally,	 MD	 could	 be	 used	 to	 assess	 liver	 metabolism	
and	 explore	 new	 viability	 criteria	 during	 normothermic	



























rameters	 with	 clinically	 relevant	 endpoints	 and	 possibly	
exploring	further	applications	of	MD	in	machine	perfusion.
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